STUDY OF BSG (BASIGIN, CD147) GENE EXPRESSION IN EGYPTIAN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Acute Myeloid leukemia (AML) is a clonal proliferation of myeloid blasts in the peripheral blood, bone marrow, or other tissues. Molecular markers have made a breakthrough in AML after proving to be important in disease pathogenesis and as therapeutic targets. Basigin (BSG, CD147), also named as extracellular MMP inducer (EMMPRIN), is a widely distributed cell surface glycoprotein that belongs to the immunoglobulin superfamily. BSG expression is elevated in many cancers and is known to promote tumor invasiveness and metastasis, through interaction with various proteins. It has been explored as a potential biomarker for cancer diagnosis and prognosis, as well as a therapeutic target. Recent studies have shown growing interest in the CD147 molecule in some hematological malignancies and highlighted its significant role in the pathogenesis. However, minimal studies have been conducted to evaluate the role of BSG gene expression in adult AML.AIM:The aim of the present study was to assess the impact of BSG gene expression on the susceptibility and clinical outcome among Egyptian patients with acute myeloid leukemia.SUBJECTS AND METHODS:SUBJECTS: This study was conducted on 50newly diagnosed adult AML patients of both sexes admitted to Alexandria Main University Hospital and 50 individuals of matching age and sex as a control group, that were clinically and laboratory free from hematological malignancies.